SLC5A2 and diabetes mellitus: The compounds tested were: (1) fingolimod, a spingosine-1 agonist, showing cardioprotection in several models (11, 12), (2) empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, a novel clinical diabetes and heart failure medicine class, showing promise as cardioprotective agent for cardiac IRI (13), (3) melatonin, an antioxidant, demonstrating protection in various models of cardiac IRI (14, 15), and (4) nicotinamide riboside (NR), a precursor of the reducing compound NAD+, known to be depleted during ischemia (16).